Synthaverse

Synthaverse FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Synthaverse (SVE.WA) as of Oct 17, 2026 is 104.40 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -372.33 % — a change of -128.04% (higher).

FCF Conversion

104.40 %

YoY

-128.04%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Synthaverse is 2025 104.40 % . FCF Conversion Rate (FCF/EBITDA) of Synthaverse was 2024 -372.33 % . It decreases by -128.04% higher compared to the previous year.

The Synthaverse FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
10.07 PLN
Jan 1, 2019
296.17 PLN
Jan 1, 2020
-37.89 PLN
Jan 1, 2021
-510.92 PLN
Jan 1, 2022
-555.94 PLN
Jan 1, 2023
-2,478.90 PLN
Jan 1, 2024
-372.33 PLN
Jan 1, 2025
104.40 PLN
The Synthaverse FCF Conversion history
YEARFCF ConversionYoY
104.40 %-128.04%
-372.33 %-84.98%
-2,478.90 %+345.89%
-555.94 %+8.81%
-510.92 %+1,248.38%
-37.89 %-112.79%
296.17 %+2,841.05%
10.07 %-98.47%
658.50 %-1,537.38%
-45.81 %-138.05%
120.40 %-105.03%
-2,391.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synthaverse Stock analysis

What does Synthaverse do? Biomed Lublin is a Polish company that has been active in the production of serums and vaccines since 1950. It has grown to become a leading producer of biological substances and medical devices in Eastern Europe. The company was originally a state institution for the development of animal vaccines but was privatized after the political changes in the late 1980s. Since 2002, it has been listed on the Warsaw Stock Exchange and has expanded its focus. Biomed Lublin operates in four main areas: veterinary medicine, human medicine, diagnostics, and laboratory equipment. It has a strong reputation in the veterinary medicine field, offering vaccines and diagnostics for livestock and pets. The company is also involved in human medicine, producing vaccines and diagnostics exclusively in Poland. In the diagnostics field, Biomed Lublin has developed and manufactured a variety of test kits used in medical diagnostics. It also offers laboratory equipment such as microscopes, pipettes, and centrifuges for medical and biological testing in hospitals and laboratories. Overall, Biomed Lublin aims to continue expanding its presence in the biotech industry in Eastern Europe and providing high-quality and effective diagnostic and therapeutic solutions to improve the health of both humans and animals. Synthaverse is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Synthaverse stock

FCF Conversion Rate (FCF/EBITDA) of Synthaverse is 104.40 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Synthaverse changed from -372.33 % to 104.40 %, representing a -128.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Synthaverse since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Synthaverse with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Synthaverse

All Key Metrics — Synthaverse